Stem Cell Club

Directions Website

Stem Cell Club High-Quality MSC Stem Cells
Without the $15,000 Price Tag

10/19/2026

Here is where it all start. Viable

Here's the worry most people have about a free consult: that it's a sales pitch in disguise.Fair worry. So here's what a...
10/19/2026

Here's the worry most people have about a free consult: that it's a sales pitch in disguise.

Fair worry. So here's what a consult should be, with us or with anyone.

It's for questions. You shouldn't feel pushed to decide or pay on the call.
You should get straight answers, including "we don't know" when that's the honest answer.
You should be able to see the COA for the exact lot, and the total cost in writing, before you commit to anything.
And if it isn't a fit for you, you should hear that too.

If you feel rushed, slow down. Pressure to decide fast or pay up front is a red flag anywhere.

Ours is free, 15 minutes, by phone or Zoom. Bring yesterday's question list. If we're not a fit, we'll tell you honestly. And talk with your own doctor too. They know your history.

Book through the link in bio.

Jesse is the Club's AI-generated guide, not a clinician. (Image is AI-generated.)

Source: ISSCR, "9 Things to Know About Stem Cell Treatments" (closerlookatstemcells.org).

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

Is a thawed cell the same as a fresh one?Not always. And it's a fair question, because most cell products are frozen for...
10/18/2026

Is a thawed cell the same as a fresh one?

Not always. And it's a fair question, because most cell products are frozen for storage and shipping.

Here's one study that looked at it. In a 2012 lab study from McGill University, researchers compared MSCs from healthy volunteers right after thawing with MSCs kept growing in culture. The freshly thawed cells were less able to suppress T-cell growth in a lab test. After 24 hours back in culture, that activity returned.

What it doesn't tell you: this was a lab study, in a dish, not a human trial. It says nothing about how any product will do in a person. More research is needed.

What it does tell you: what happens after the thaw is worth paying attention to. So is the timing of a viability test. A number measured before freezing describes the cells before the freeze-thaw cycle. A post-thaw number describes them after it, which is closer to what's actually given.

So ask one question: was this viability tested pre-freeze or post-thaw, by what method, and on what date?

The drawing is an illustration, not a photo of any product.

Sources: François et al., Cytotherapy 2012 (PMID 22029655). Cottle et al., Curr Stem Cell Rep 2022 (PMID 35502223).

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

You don't need a science degree to read a stem cell lab report. You need four ideas. Here's what we covered this week.1....
10/18/2026

You don't need a science degree to read a stem cell lab report. You need four ideas. Here's what we covered this week.

1. Do the math.
Viable cell count = total cell count Ă— viability %. A big total with low viability means fewer live cells. Ask for both numbers.

2. Viability varies.
In the START trial, a phase 2a study of 60 participants, the viability of the MSC doses given ranged from 36% to 85%. The authors wrote that "the viability of MSCs must be improved." Freezing, storage, shipping, and thawing all play a part, so the numbers can vary from lot to lot. Researchers are still working on this, and more research is needed.

3. Three tests, three questions.
Viability asks: are the cells alive? Identity asks: what type of cells are they? For MSCs, that means markers like CD73, CD90, and CD105. Potency asks: how well do they function? One number can't answer all three.

4. Labels aren't approval.
A lab being "FDA-registered" isn't FDA approval of a product. "361 HCT/P" isn't approval either. It's a regulatory category with its own criteria.

The short version: ask for the COA for your exact lot, and read past the first number.

Save this one. It's the whole week in a minute.

Sources: Matthay et al., Lancet Respir Med 2019 (PMID 30455077; NCT02097641). Dominici et al., Cytotherapy 2006 (PMID 16923606). 21 CFR 1271.10. FDA consumer guidance.

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

Most people walk into a consult with hope and no list. Bring the list.Jesse, the Club's AI-generated guide, keeps this o...
10/18/2026

Most people walk into a consult with hope and no list. Bring the list.

Jesse, the Club's AI-generated guide, keeps this one simple. Four things to bring:

1. Your questions, written down. Nerves make everyone forget.
2. A list of your current medications and supplements.
3. Input from your own doctor, if you've talked with them first. It's worth doing.
4. A way to take notes, or someone to come along.

And the questions worth writing down:
What's this product's FDA status: approved, studied under an IND or a clinical trial, or neither?
Can I see the COA for the exact lot I'd receive?
Is viability measured post-thaw, by what method, and on what date?
Who administers it, and what are the known risks?
What's the total cost, in writing?

A good clinic should be glad you asked. If they aren't, that tells you something too.

Save this post so it's on your phone when you need it.

Jesse is the Club's AI-generated guide, not a clinician. (Image is AI-generated.)

Sources: ISSCR, "9 Things to Know About Stem Cell Treatments" (closerlookatstemcells.org). FDA consumer guidance on regenerative medicine.

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

đŸ”¬ Research spotlight: same trial, same data, two different readings.The trial is HOPE-3. It's a phase 3, randomized, dou...
10/17/2026

đŸ”¬ Research spotlight: same trial, same data, two different readings.

The trial is HOPE-3. It's a phase 3, randomized, double-blind, placebo-controlled study of deramiocel, an investigational cell therapy made from donor heart cells (cardiosphere-derived cells, not MSCs). It enrolled 106 people aged 10 and older with Duchenne muscular dystrophy: 54 got deramiocel, 52 got placebo. The maker, Capricor, funded it.

Reading one: the paper. Published in The Lancet in 2026, it reported that the primary endpoint, upper-limb function at 12 months measured as a percent change, favored deramiocel by 4.55 percentage points (p=0.029). The authors reported a safety profile similar to placebo.

Reading two: FDA's reviewers. Their briefing document says that analysis plan was finalized one day before the database was locked and the data unblinded. Using the analysis originally prespecified, FDA found a difference of 0.66 points (p=0.24) and called it neither statistically significant nor clinically meaningful.

In July 2026, an FDA advisory committee voted 9 to 3 "no" on whether the evidence was strong enough for the heart-related use the company had proposed. That vote is non-binding. The company says FDA's target decision date is November 22, 2026.

Why should you care? Because how a study is analyzed can change what it seems to show. That's why researchers are supposed to write the plan down before they look.

So the next time someone says "a study showed," ask one question: was that the analysis they planned up front?

More research, and FDA's review, will tell us more. This is about one investigational product. It doesn't carry over to any other cell product.

We walked through both readings on the blog. Link in bio.

Sources: McDonald et al., Lancet 2026 (PMID 42526472; NCT05126758). FDA briefing document, Cellular, Tissue, and Gene Therapies Advisory Committee, July 29, 2026.

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

Here's a number most people never get to see.START was a phase 2a trial of 60 participants, published in The Lancet Resp...
10/17/2026

Here's a number most people never get to see.

START was a phase 2a trial of 60 participants, published in The Lancet Respiratory Medicine in 2019. The researchers measured the viability of the MSC doses they gave. Viability is the share of cells alive when tested.

It ranged from 36% to 85%.

Same trial. Same protocol. And the share of live cells still varied by almost 50 percentage points from dose to dose.

The authors wrote it plainly: "the viability of MSCs must be improved."

That's not a knock on research. It's honest research. Reviews of cryopreservation note that freeze rate, cryoprotectant, storage and shipping temperature, and thaw technique can all affect post-thaw numbers, so the numbers can vary from lot to lot. Researchers are still working on better ways to freeze and thaw cells, and more research is needed.

Here's the lesson. Viability isn't a fixed trait of "stem cells." It's a measurement of one lot, at one point in time.

So ask three things:
What's the post-thaw viability for the exact lot I'd receive?
What method was used, and on what date?
Can I see it on that lot's COA?

And keep it in proportion. Viability tells you cells were alive when tested. It doesn't predict how anything goes for you. Medical questions belong with your own licensed provider.

The drawing is an illustration, not a photo of any product.

Sources: Matthay et al., Lancet Respir Med 2019 (PMID 30455077; NCT02097641). Cottle et al., Curr Stem Cell Rep 2022 (PMID 35502223).

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

Three phrases that show up a lot in this space: 361 HCT/P, minimal manipulation, and homologous use.They sound like jarg...
10/17/2026

Three phrases that show up a lot in this space: 361 HCT/P, minimal manipulation, and homologous use.

They sound like jargon. They're actually regulatory categories under FDA rules for human cell and tissue products (HCT/Ps).

Under 21 CFR 1271.10, some HCT/Ps are regulated only under section 361 of the Public Health Service Act if they meet certain criteria. Two of those criteria are "minimal manipulation" and "homologous use." Products that don't meet the criteria generally need a different pathway, such as an investigational new drug (IND) application, instead of the 361 route.

What that means for you as a consumer is simple: the regulatory path for a product matters. "361" is a category. It is not the same as FDA product approval.

Most stem cell offerings are not FDA-approved. When you hear those three phrases, ask:
Is this product regulated as a 361 HCT/P, or does it need a different pathway such as an IND?
What does the clinic mean by "minimal manipulation" and "homologous use" for this exact product?
Can I see that in writing, along with the COA for the lot I'd receive?

Take medical questions to your own licensed provider.

Source: 21 CFR 1271.10 (eCFR). FDA consumer guidance on regenerative medicine.

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

Myth: more cells always means better.Fact: cell count, viability, and identity are three separate measures.A big total c...
10/16/2026

Myth: more cells always means better.

Fact: cell count, viability, and identity are three separate measures.

A big total count with low viability means fewer live cells. That's just arithmetic: viable cell count = total count Ă— viability %.

And even a high viability number only tells you cells were alive when tested. It doesn't tell you what type of cells they are. That's identity, which needs its own markers. And it doesn't tell you how well they function. That's potency, another set of tests.

In one lab study, MSCs kept high post-thaw viability after brief warming but lost function. So a big number on its own is not the whole story.

When you see a cell count, ask three plain questions:
What's the viability for that exact lot?
Was it measured post-thaw, and by what method?
Are identity markers on the COA too?

Talk with your own doctor about any medical questions.

Sources: Cai et al., Cytotherapy 2024 (PMID 38085197). Dominici et al., Cytotherapy 2006 (PMID 16923606). Galipeau 2016 (PMID 26724220). Chabot et al., Cytotherapy 2018 (PMID 30093326).

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

The brochure and the COA are not the same document.Jesse, the Club's AI-generated guide, has seen this one a lot.Brochur...
10/16/2026

The brochure and the COA are not the same document.

Jesse, the Club's AI-generated guide, has seen this one a lot.

Brochure: "millions of cells."
COA: a cell count… and sometimes nothing about whether those cells were alive when tested. No test method. No lot number that matches the vial.

Those are different pieces of paper with different jobs.

Cell count is how many cells are there. Viability is the share that are alive when tested. They're separate numbers. And viability still isn't identity (what type of cells) or potency (how well they function). Those need their own tests.

So if you're handed a brochure, ask for the COA for the exact lot. Then check three things:
Is viability on it?
What method, and was it post-thaw?
Does the lot number match the vial?

Medical questions belong with your own licensed provider.

Jesse is the Club's AI-generated guide, not a clinician. (Image is AI-generated.)

Sources: Cai 2024; Dominici 2006; Galipeau 2016.

Educational only, not medical advice. Stem cell offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease. Individual results vary.

Address

640 E 700 S STE 304
Saint George, UT
84790

Website

Alerts

Be the first to know and let us send you an email when Stem Cell Club posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category